ReviewClinical microbiology reviews2022
Clinical and Public Health Implications of Human T-Lymphotropic Virus Type 1 Infection.
Review in Clinical microbiology reviews, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Molecular biomarkers associated with ATLL and HAM progression in HTLV-1 infection: a systematic review.Revista do Instituto de Medicina Tropical de Sao Paulo · 2026Pooled it
- HTLV-1-associated diseases: a systematic review.Revista do Instituto de Medicina Tropical de Sao Paulo · 2026Pooled it
- Low Prevalence of Human T-Cell Lymphotropic Virus Type 1 (HTLV-1) in a Hospital Triage Population in Tehran During 2024-2025.Health science reports · 2026Article
- Emerging Risk for Human T-Cell Leukemia Virus Type 1 Transmission with HIV-Positive Breastfeeding Support.Emerging infectious diseases · 2026Review
- Distribution of adult T-cell leukaemia/lymphoma subtypes and survival outcomes across geographical regions: An international retrospective cohort study.British journal of haematology · 2026Article
- Primary causes of hospital admission in HTLV-1 infected patients: infectious complications, predictors of mortality and long-term survival outcomes.BMC infectious diseases · 2026Article
- Integrated in vitro and multi-cohort cross-omics analysis of HTLV-1-associated lung pathology reveals a RelA-dependent mechanism for monocyte recruitment and differentiation.Molecular medicine (Cambridge, Mass.) · 2026Article
- Article
- Morbidity and Mortality Among People Living With HTLV-1: A 30-Year Retrospective Analysis in a Brazilian Cohort.Journal of medical virology · 2026Article
- Seroprevalence Assessment of HTLV-1 and Its Related Risk Factors in Patients With Rheumatoid Arthritis in Gonabad in 2023.Clinical medicine insights. Arthritis and musculoskeletal disorders · 2026Article
- Epidemiology and Clinical Outcomes of HTLV-1: A Comprehensive Narrative Review of Endemic and Nonendemic Regions.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026Review
- A Review of Cutaneous Viral Infections and Their Potential Role in Neurologic Diseases.Journal of clinical medicine · 2025Review
- Article
- Article
- A Framework for Evaluation of New Processing Technologies in Human Milk Banking.Comprehensive reviews in food science and food safety · 2025Review
- Prevalence of human T-cell lymphotropic virus type 1 or 2 among blood donors screened at the New Zealand Blood Service: An observational study, 2001-2024.Preventive medicine reports · 2025Article
- A Simple, Highly Sensitive, and Highly Specific Dot-Blot-Based Immunoassay for Serodiagnosis of HTLV-1 in Resource-Limited Settings.Tropical medicine and infectious disease · 2025Article
- High Rate of Human T-Cell Lymphotropic Virus-2 in Patients with HIV in the Peruvian Amazon.Tropical medicine and infectious disease · 2025Article
- Efgartigimod Combined With Steroid Treatment for HAM/TSP: A Case Report.Annals of clinical and translational neurology · 2025Article
- Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human T-lymphotropic virus type 1 (HTLV-1) is estimated to affect 5 to 10 million people globally and can cause severe and potentially fatal disease, including adult T-cell leukemia/lymphoma (ATL) and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). The burden of HTLV-1 infection appears to be geographically concentrated, with high prevalence in discrete regions and populations. While most high-income countries have introduced HTLV-1 screening of blood donations, few other public health measures have been implemented to prevent infection or its consequences. Recent advocacy from concerned researchers, clinicians, and community members has emphasized the potential for improved prevention and management of HTLV-1 infection. Despite all that has been learned in the 4 decades following the discovery of HTLV-1, gaps in knowledge across clinical and public health aspects persist, impeding optimal control and prevention, as well as the development of policies and guidelines. Awareness of HTLV-1 among health care providers, communities, and affected individuals remains limited, even in countries of endemicity. This review provides a comprehensive overview on HTLV-1 epidemiology and on clinical and public health and highlights key areas for further research and collaboration to advance the health of people with and at risk of HTLV-1 infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.